These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33278335)

  • 81. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
    Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
    Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
    Sermsathanasawadi N; Sritongsathian C; Pongrattanaman N; Praditsuktavorn B; Hongku K; Wongwanit C; Ruangsetakit C; Chinsakchai K; Mutirangura P; Poungvarin N
    J Med Assoc Thai; 2015 Jun; 98(6):549-54. PubMed ID: 26219158
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients.
    Tanaka T; Ihara M; Fukuma K; Yamamoto H; Washida K; Kimura S; Kada A; Miyata S; Miyata T; Nagatsuka K
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680932
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
    Li X; Liu R; Yan H; Tang J; Yin JY; Mao XY; Yang F; Luo ZY; Tan SL; He H; Chen XP; Liu ZQ; Li Z; Zhou HH; Zhang W
    J Clin Pharmacol; 2015 Mar; 55(3):251-7. PubMed ID: 25187307
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
    Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
    Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pathway analysis of genome-wide data improves warfarin dose prediction.
    Daneshjou R; Tatonetti NP; Karczewski KJ; Sagreiya H; Bourgeois S; Drozda K; Burmester JK; Tsunoda T; Nakamura Y; Kubo M; Tector M; Limdi NA; Cavallari LH; Perera M; Johnson JA; Klein TE; Altman RB
    BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S11. PubMed ID: 23819817
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 96. VKORC1 and CYP2C9 genotype distribution in Asian countries.
    Gaikwad T; Ghosh K; Shetty S
    Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.
    Kamal El-Din MA; Farhan MS; El Shiha RI; El-Kaffas RM; Mousa SM
    Paediatr Drugs; 2014 Aug; 16(4):337-41. PubMed ID: 24797541
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.
    Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC
    Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
    Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
    Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.